Prostaglandin E2 and vasoactive intestinal peptide increase vascular endothelial cell growth factor mRNAs in lung cancer cells

This publication has 22 references indexed in Scilit:

• Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin‐1: a potential mechanism for inflammatory angiogenesis
  Published by Wiley ,2000
• Tissue-specific expression pattern of vascular endothelial growth factor isoforms in the malignant transformation of lung and colon
  Human Pathology, 1998
• Vascular endothelial growth factor and nitric oxide synthase expression in human lung cancer and the relation to p53
  British Journal of Cancer, 1998
• High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer
  International Journal of Cancer, 1998
• A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth.
  Proceedings of the National Academy of Sciences, 1993
• The fms -Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor
  Science, 1992
• The Vascular Endothelial Growth Factor Family: Identification of a Fourth Molecular Species and Characterization of Alternative Splicing of RNA
  Molecular Endocrinology, 1991
• Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels.
  The Journal of Experimental Medicine, 1991
• Insulin-like growth factor-I can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro.
  Journal of Clinical Investigation, 1988
• Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer
  Nature, 1985